OncoMatch/Clinical Trials/NCT05093231
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Is NCT05093231 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Olaparib for pancreatic cancer.
Treatment: Pembrolizumab · Olaparib — A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Excluded: Stage RESECTABLE, III
Metastatic disease required
Radiologically confirmed stage 4 mPDA, with measurable disease; Patients with resectable or locally advanced PDA [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior immune checkpoint inhibitors or PARP inhibitors. This includes any prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g, CTLA-4, OX 40, CD137)
Cannot have received: PARP inhibitor
Prior immune checkpoint inhibitors or PARP inhibitors.
Cannot have received: systemic anti-cancer therapy
Exception: within 4 weeks prior to screening
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to screening.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention; 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L; Hb ≥ 90 g/L; platelets ≥100 x 10^9/L
Kidney function
creatinine clearance by Cockcroft-Gault ≥50 mL/min
Liver function
AST or ALT ≤2.5 x ULN, or <5 x ULN in the presence of liver metastases; total bilirubin <1.5 x ULN
Adequate bone marrow function: ANC ≥1.5 x 10^9/L, Hb ≥ 90 g/L, platelets ≥100 x 10^9/L; Adequate liver function: AST or ALT ≤2.5 x ULN, or <5 x ULN in the presence of liver metastases; total bilirubin <1.5 x ULN; Adequate renal function: creatinine clearance by Cockcroft-Gault ≥50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05093231 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, PARP inhibitor, systemic anti-cancer therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages